MetaCap

Abeona Therapeutics Inc. (ABEO)

NASDAQ: ABEOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.42-0.03 (-1.22%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABEO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$165.31M
EPS (TTM)
-$1.16
Ex-dividend date
Mar 31, 2000
52-week range
2.09 – 7.65
Day range
2.40 – 2.57
Volume / Avg
4.72M / 1.66M
Beta
—

52-week range

$2.09$7.65

ABEO stock today

Shares of Abeona Therapeutics (ABEO) finished lower on Nov 20 at $2.42, a drop of 1.22% or $0.03 per share, versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 4.72M shares, a sign of unusually heavy trading. Shares are 68.4% below their 52-week high of $7.65, set on Aug 11, 2026 and 15.8% above the 52-week low of $2.09, near the bottom of the past year's range.

ABEO is down 54.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.0%. Abeona Therapeutics has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Abeona Therapeutics

Company profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Headquarters
Cleveland, OH
Employees
226

Financial highlights

Full financials

In fiscal 2025, Abeona Therapeutics generated $5.8 million in revenue. Net income was $71.2 million, for a net margin of 1223.1% versus a median of -2177.8% in the prior 5 years. Gross margin was 73.7% and operating margin -1536.9%.

Abeona Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$5.82M—$3.50M$1.41M$3.00M
Growth——+147.52%-52.87%-70.00%
Net income$71.18M$-63.73M$-54.19M$-39.70M$-84.94M
EPS (diluted)$1.01$-1.55$-2.53$-5.53$-0.86

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$15.56+542.98%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $7.50High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.08 vs $-0.14
Surprise
+42.86%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$3,706.25
Ex-dividend date
Mar 31, 2000

ABEO news

All ABEO news

Abeona Therapeutics peers

Health Care sector
ABEO peer companies
CompanyPrice% ChgMarket capCompare
KRROKorro Bio Inc.12.18-0.08%$167.18Mvs ABEO
TRDAEntrada Therapeutics Inc.4.35-6.25%$170.30Mvs ABEO
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs ABEO
SIGASIGA Technologies Inc.2.40-9.43%$172.45Mvs ABEO
VOGXVogenx Inc11.87-7.30%$176.33Mvs ABEO
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs ABEO
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs ABEO
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs ABEO

Indexes, lists and sector

Abeona Therapeutics stock FAQ

What is Abeona Therapeutics's stock price today?

ABEO last traded at $2.42 as of Nov 20, 4:00 PM EST, down 1.22% on the day. Prices are delayed at least 15 minutes.

Does Abeona Therapeutics pay a dividend?

Yes. Abeona Therapeutics pays $0.00 per share annually. The most recent dividend of $3,706.25 had an ex-dividend date of Mar 31, 2000.

Who is Abeona Therapeutics's CEO?

Dr. Vishwas Seshadri M.B.A., Ph.D. is the chief executive officer of Abeona Therapeutics Inc., which has about 226 employees.

Has ABEO ever split its stock?

Yes. The most recent ABEO stock split was a 1-for-25 split on Jul 5, 2022, one of 5 splits on record.

What is the ABEO 52-week high?

The 52-week high for ABEO is $7.65 and the 52-week low is $2.09. The stock is currently 68.4% below its high.

Compare ABEO